338 related articles for article (PubMed ID: 33289297)
1. Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m
Danne T; Edelman S; Frias JP; Ampudia-Blasco FJ; Banks P; Jiang W; Davies MJ; Sawhney S
Diabetes Obes Metab; 2021 Mar; 23(3):854-860. PubMed ID: 33289297
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials.
Musso G; Gambino R; Cassader M; Paschetta E
BMJ; 2019 Apr; 365():l1328. PubMed ID: 30967375
[TBL] [Abstract][Full Text] [Related]
3. Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes.
Danne T; Pettus J; Giaccari A; Cariou B; Rodbard H; Weinzimer SA; Bonnemaire M; Sawhney S; Stewart J; Wang S; Castro RC; Garg SK
Diabetes Technol Ther; 2019 Sep; 21(9):471-477. PubMed ID: 31335194
[No Abstract] [Full Text] [Related]
4. Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials.
Boeder S; Edelman SV
Diabetes Obes Metab; 2019 Apr; 21 Suppl 2(Suppl 2):62-77. PubMed ID: 31081593
[TBL] [Abstract][Full Text] [Related]
5. HbA
Danne T; Cariou B; Banks P; Brandle M; Brath H; Franek E; Kushner JA; Lapuerta P; McGuire DK; Peters AL; Sawhney S; Strumph P
Diabetes Care; 2018 Sep; 41(9):1981-1990. PubMed ID: 29937431
[TBL] [Abstract][Full Text] [Related]
6. Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
Garg SK; Henry RR; Banks P; Buse JB; Davies MJ; Fulcher GR; Pozzilli P; Gesty-Palmer D; Lapuerta P; Simó R; Danne T; McGuire DK; Kushner JA; Peters A; Strumph P
N Engl J Med; 2017 Dec; 377(24):2337-2348. PubMed ID: 28899222
[TBL] [Abstract][Full Text] [Related]
7. Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.
Danne T; Cariou B; Buse JB; Garg SK; Rosenstock J; Banks P; Kushner JA; McGuire DK; Peters AL; Sawhney S; Strumph P
Diabetes Care; 2019 May; 42(5):919-930. PubMed ID: 30833371
[TBL] [Abstract][Full Text] [Related]
8. Sotagliflozin: A Review in Type 1 Diabetes.
Deeks ED
Drugs; 2019 Dec; 79(18):1977-1987. PubMed ID: 31761990
[TBL] [Abstract][Full Text] [Related]
9. Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial.
Baker C; Wason S; Banks P; Sawhney S; Chang A; Danne T; Gesty-Palmer D; Kushner JA; McGuire DK; Mikell F; O'Neill M; Peters AL; Strumph P
Diabetes Obes Metab; 2019 Nov; 21(11):2440-2449. PubMed ID: 31264767
[TBL] [Abstract][Full Text] [Related]
10. Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2.
Rodbard HW; Giaccari A; Cariou B; Garg S; Davies MJ; Seth K; Sawhney S
Diab Vasc Dis Res; 2021; 18(1):1479164121995928. PubMed ID: 33611925
[TBL] [Abstract][Full Text] [Related]
11. Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.
Sands AT; Zambrowicz BP; Rosenstock J; Lapuerta P; Bode BW; Garg SK; Buse JB; Banks P; Heptulla R; Rendell M; Cefalu WT; Strumph P
Diabetes Care; 2015 Jul; 38(7):1181-8. PubMed ID: 26049551
[TBL] [Abstract][Full Text] [Related]
12. Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.
Buse JB; Garg SK; Rosenstock J; Bailey TS; Banks P; Bode BW; Danne T; Kushner JA; Lane WS; Lapuerta P; McGuire DK; Peters AL; Reed J; Sawhney S; Strumph P
Diabetes Care; 2018 Sep; 41(9):1970-1980. PubMed ID: 29937430
[TBL] [Abstract][Full Text] [Related]
13. Effects of Sotagliflozin Combined with Intensive Insulin Therapy in Young Adults with Poorly Controlled Type 1 Diabetes: The JDRF Sotagliflozin Study.
Bode BW; Cengiz E; Wadwa RP; Banks P; Danne T; Kushner JA; McGuire DK; Peters AL; Strumph P; Sawhney S
Diabetes Technol Ther; 2021 Jan; 23(1):59-69. PubMed ID: 32640846
[No Abstract] [Full Text] [Related]
14. Sotagliflozin: a dual sodium-glucose co-transporter-1 and -2 inhibitor for the management of Type 1 and Type 2 diabetes mellitus.
Sims H; Smith KH; Bramlage P; Minguet J
Diabet Med; 2018 Aug; 35(8):1037-1048. PubMed ID: 29637608
[TBL] [Abstract][Full Text] [Related]
15. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives.
Cefalo CMA; Cinti F; Moffa S; Impronta F; Sorice GP; Mezza T; Pontecorvi A; Giaccari A
Cardiovasc Diabetol; 2019 Feb; 18(1):20. PubMed ID: 30819210
[TBL] [Abstract][Full Text] [Related]
16. Sotagliflozin added to optimized insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: A pooled analysis of inTandem1 and inTandem2.
Rodbard HW; Giaccari A; Lajara R; Stewart J; Strumph PS; Oliveira J; Lapuerta P; Castro R
Diabetes Obes Metab; 2020 Nov; 22(11):2089-2096. PubMed ID: 32618383
[TBL] [Abstract][Full Text] [Related]
17. Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination.
Jendle JH; Ampudia-Blasco FJ; Füchtenbusch M; Pozzilli P
touchREV Endocrinol; 2021 Apr; 17(1):12-20. PubMed ID: 35118442
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment.
Cherney DZI; Ferrannini E; Umpierrez GE; Peters AL; Rosenstock J; Carroll AK; Lapuerta P; Banks P; Agarwal R
Diabetes Obes Metab; 2021 Dec; 23(12):2632-2642. PubMed ID: 34338408
[TBL] [Abstract][Full Text] [Related]
19. Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With Type 1 Diabetes: A Network Meta-Analysis.
Kim YJ; Hwang SD; Lim S
Front Endocrinol (Lausanne); 2020; 11():553. PubMed ID: 32973680
[TBL] [Abstract][Full Text] [Related]
20. Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials.
Yamada T; Shojima N; Noma H; Yamauchi T; Kadowaki T
Diabetes Obes Metab; 2018 Jul; 20(7):1755-1761. PubMed ID: 29451721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
